Citations

Clear

3042 citation(s) found for "Kumar, S".

Preventive PCI versus culprit lesion stenting during primary PCI in acute STEMI: a systematic review and meta-analysis
Pandit, Anil , Aryal, Madan Raj , Pandit, Aashrayata Aryal, Hakim, Fayaz A., Mainali, Naba Raj , Lee, Howard R., Fortuin, F. David , Mookadam, Farouk , Aryal Pandit, Aashrayata, Hakim, Fayaz Ahmad, Sharma, Prashant , Giri, Smith , Sharma, Prashant Kumar , Mookadam, Farouk

Mayo Clinic

Open Heart | February 18, 2014 | Volume: 1 | Issue: 1 | Pages: e000012

10.1136/openhrt-2013-000012 | PMID 25332779 Get It

Aim The benefit of preventive percutaneous coronary intervention (PCI) in ST elevation myocardial infarction (STEMI) has been shown in randomised trials. However, all the randomised trials are underpowered to detect benefit in cardiac death. We aim to systematically review evidence on the cardiac mortality benefit of preventive PCI in patients presenting with acute STEMI in randomised patient populations. Methods PubMed, Scopus, Cochrane and clinicaltrials.gov databases were searched for studies published until 30 September 2013. The studies were limited to randomised clinical trials. Independent observers abstracted the data on outcomes, characteristics and qualities of studies included. Fixed effect model was employed for meta-analysis. Heterogeneity of studies included was analysed using I2 statistics. Results In three randomised clinical trials published, involving 748 patients with acute STEMI and multivessel disease, 416 patients were randomised to preventive PCI and 332 to culprit-only PCI. Patients undergoing preventive PCI had significant lower risk of cardiovascular deaths (pooled OR 0.39, 95% CI 0.18 to 0.83, p=0.01, I2=0%), repeat revascularisation (pooled OR 0.28, 95% CI 0.18 to 0.44, p=0.00001, I2=0%) and non-fatal myocardial infarction (pooled OR 0.38, 95% CI 0.20 to 0.75, p=0.005, I2=0%) compared with culprit-only revascularisation. Conclusions In patients presenting with acute STEMI and significant multivessel coronary artery disease, based on our data, preventive PCI is associated with lower risk of cardiovascular mortality compared with primary PCI of only the culprit artery. This finding needs to be confirmed in larger adequately powered randomised clinical trials.
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant
Warsame, Rahma , Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Kyle, Robert A. , Leung, Nelson , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Dispenzieri, Angela , Bang, Soo‐Mee , Gertz, Morie A. , Buadi, Francis K. , Witzig, Thomas E. , Rajkumar, S. Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

European Journal of Haematology | February 6, 2014 | Volume: 92 | Issue: 6 | Pages: 485-490

10.1111/ejh.12282 | PMID 24502602 Get It

AbstractImmunoglobulin light chain (AL) Amyloidosis is a condition whereby misfolded proteins generated by plasma cells deposit in tissues causing organ dysfunction. Chemotherapy and autologous stem cell transplant when eligible are standard treatment options. Several studies report long‐term outcomes of patients post‐transplant. However, there is a paucity of literature describing outcomes of relapsed patients post‐transplant. We performed a retrospective study to assess outcomes and therapies employed upon relapse after transplant. Between 1996 and 2009, 410 patients received transplant at the Mayo Clinic as first‐line therapy. Of those patients, 42 (10%) died within 3 months of transplant, 64 (16%) died without documented relapse, 158 (38%) were alive without documented progression, and 146 (36%) had documented progression. Those 146 patients are the subject of our study, and their median time to hematologic relapse/progression was 23.6 months (95%CI 18.3, 26.3 months). Their median overall survival and 5‐yrs overall survival from post‐transplant relapse/progression was 51.7 months (95%CI 34.1–62.3) and 39%, respectively. The most common first regimen for treatment after relapse was lenalidomide or thalidomide. In conclusion, our study indicates that patients with AL amyloidosis fare well post‐transplant relapse/progression. Additionally, it provides a yardstick to design clinical trials to determine best treatment options.
Secondary Hemophagocytic Syndrome Associated with Richter’s Transformation in Chronic Lymphocytic Leukemia
El‐Haj, Nura , Smeltzer, Jacob P., Gangat, Naseema , Singh, Preet P, Gonsalves, Wilson I. , Gupta, Vinay Kumar , Parikh, Sameer A. , Singh, Preet Paul

Mayo Clinic

Case Reports in Hematology | January 19, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-4

10.1155/2014/287479 | PMID 24551464 Get It

Hemophagocytic syndrome (HPS) is an extremely rare condition arising from the overactivation of one’s own immune system. It results in excessive inflammation and tissue destruction. Prompt initiation of treatment is warranted in either scenario in order to decrease mortality. Most cases are triggered by infectious agents, malignancy, or drugs. We describe the first case of a CLL patient presenting with HPS due to acquisition of EBV-related large cell lymphoma in the setting of profound immunodeficiency.
A Lifetime of Hypercalcemia and Hypercalciuria, Finally Explained
Jacobs, Thomas P., Kaufman, Martin, Jones, Glenville , Schlingmann, Karl P. , Shapses, Sue A. , Bilezikian, John P. , Kumar, Rajiv

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 14, 2014 | Volume: 99 | Issue: 3 | Pages: 708-712

10.1210/jc.2013-3802 | PMID 24423361 Get It

Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK
Liu, Xiaona , Chhipa, Rishi Raj , Pooya, Shabnam, Wortman, Matthew D. , Yachyshin, Sara, Chow, Lionel M.L. , Zhou, Xuan , McPherson, Christopher, Warnick, Ronald E. , Kendler, Ady , Poels, Jeroen, Norga, Koen , Viollet, Benoı̂t , Grabowski, Gregory A. , Dasgupta, Biplab , Kumar, Ashish , Sun, Ying Hao , Quinn, Brian , Giri, Shailendra , Viollet, Benoit

Mayo Clinic

Proceedings of the National Academy of Sciences | January 13, 2014 | Volume: 111 | Issue: 4 | Pages: No page available

10.1073/pnas.1311121111 | PMID 24474794 Get It

Significance Cancer cells reprogram their metabolism for optimal growth and survival. AMPK-activated protein kinase (AMPK) is a key energy sensor that controls many metabolic pathways including metabolic reprogramming. However, its role in cancer is poorly understood. Some studies claim that it has a tumor suppressor role while others show its protumor role. Two AMPK-activating compounds (including metformin, now in many clinical trials) are widely used to suppress cancer cell proliferation. We found that AMPK is abundantly expressed in high-grade gliomas and, in contrast to popular belief, these two AMPK activators suppressed glioma cell proliferation through unique AMPK-independent mechanisms.
Population-Based Study of Severe Hypoglycemia Requiring Emergency Medical Service Assistance Reveals Unique Findings
Parsaik, Ajay K. , Carter, Rickey E. , Pattan, Vishwanath , Kumar, Hamit, Smith, Steven A., Russi, Christopher S. , Levine, James A. , Basu, Ananda , Kudva, Yogish C. , Myers, Lucas A. , Carter, Rickey E

Mayo Clinic

Journal of Diabetes Science and Technology | January 10, 2014 | Volume: 6 | Issue: 1 | Pages: 65-73

10.1177/193229681200600109 | PMID 22401324 Get It

Objective: The objective is to report a contemporary population-based estimate of hypoglycemia requiring emergency medical services (EMS), its burden on medical resources, and its associated mortality in patients with or without diabetes mellitus (DM, non-DM), which will enable development of prospective strategies that will capture hypoglycemia promptly and provide an integrated approach for prevention of such episodes. Methods: We retrieved all ambulance calls activated for hypoglycemia in Olmsted County, Minnesota, between January 1, 2003 and December 31, 2009. Results: A total of 1473 calls were made by 914 people (DM 8%, non-DM 16%, unknown DM status 3%). Mean age was 60 ± 16 years with 49% being female. A higher percentage of calls were made by DM patients (87%) with proportionally fewer calls coming from non-DM patients (11%) (chi-square test, p < .001), and the remaining 2% calls by people with unknown DM status. Emergency room transportation and hospitalization were significantly higher in non-DM patients compared to DM patients ( p < .001) and type 2 diabetes mellitus compared to type 1 diabetes mellitus ( p < .001). Sulphonylureas alone or in combination with insulin varied during the study period ( p = .01). The change in incidence of EMS for hypoglycemia was tracked during this period. However, causality has not been established. Death occurred in 240 people, 1.2 (interquartile range 0.2–2.7) years after their first event. After adjusting for age, mortality was higher in non-DM patients compared with DM patients ( p < .001) but was not different between the two types of DM. Conclusions: The population burden of EMS requiring hypoglycemia is high in both DM and non-DM patients, and imposes significant burden on medical resources. It is associated with long-term mortality.
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
Dispenzieri, Angela , Kumar, Shaji , Lacy, Martha Q. , Kyle, Robert A. , Saenger, Amy K., Grogan, Martha , Zeldenrust, Steven R., Hayman, S. R., Greipp, Philip R., Russell, Stephen J. , Dingli, David , Lust, John A., Rajkumar, S. Vincent , Jaffe, Allan S. , Gertz, Morie A. , Buadi, Francis K. , Leung, Nelson , Jaffe, Allan S. , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

Heart | January 9, 2014 | Volume: 100 | Issue: 5 | Pages: 383-388

10.1136/heartjnl-2013-304957 | PMID 24402772 Get It

Objectives To define whether the high sensitivity cardiac troponin T (hs-cTnT) assay in patients with immunoglobulin light chain amyloidosis (AL) improves risk prediction. Background Cardiac involvement is the major cause of death in patients with AL amyloidosis. Risk stratification is facilitated by cardiac biomarkers such as cardiac troponin T (cTnT) and N-terminal pro B-type natriuretic peptide (NT-proBNP). Methods Stored serum from patients with newly diagnosed AL was used to measure hs-cTnT, cTnT, and NT-proBNP. Survival modelling was performed. Results The direct numeric result from hs-cTnT measurement cannot merely be substituted for a cTnT measurement in the Mayo AL staging system. The performance of the receiver operator curve derived an hs-cTnT cut-point of 54 ng/L which improves on the value of 35 ng/L validated with the prior iteration of the assay. An alternate staging option using hs-cTnT alone—using the two thresholds 14 ng/L and 54 ng/L—performs as well as either the original Mayo AL staging system or other systems incorporating hs-cTnT. On multivariate analysis, an hs-cTnT alone staging system was independent of period of diagnosis, type of therapy, and NT-proBNP value, the last of which dropped out of the model. Alternate models were explored, but none performed better than the original system or the new hs-cTnT system. Thus, hs-cTnT can be used alone for the staging of disease prognosis. Conclusions A survival model based on hs-cTnT improves the prognostic staging of patients with AL amyloidosis, relegating NT-proBNP to a measure of cardiac response.
Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Weroha, S. John , Becker, Marc A., Enderica-Gonzalez, Sergio, Harrington, Sean C., Oberg, Ann L. , Maurer, Matthew J. , AlHilli, Mariam , Butler, Kristina , McKinstry, Sarah, Fink, Stephanie, Jenkins, Robert B. , Hou, Xiaonan , Kalli, Kimberly R., Goodman, Karin M., Hartmann, Lynn C. , Haluska, Paul , Perkins, Sarah E. , Sarkaria, Jann N. , Karlan, Beth Y. , Kumar, Amanika , Kaufmann, Scott H. , Maurer, Matthew

Mayo Clinic

Clinical Cancer Research | January 8, 2014 | Volume: 20 | Issue: 5 | Pages: 1288-1297

10.1158/1078-0432.ccr-13-2611 | PMID 24398046 Get It

Abstract Purpose: Ovarian cancer has a high recurrence and mortality rate. A barrier to improved outcomes includes a lack of accurate models for preclinical testing of novel therapeutics. Experimental Design: Clinically relevant, patient-derived tumorgraft models were generated from sequential patients and the first 168 engrafted models are described. Fresh ovarian, primary peritoneal, and fallopian tube carcinomas were collected at the time of debulking surgery and injected intraperitoneally into severe combined immunodeficient mice. Results: Tumorgrafts demonstrated a 74% engraftment rate with microscopic fidelity of primary tumor characteristics. Low-passage tumorgrafts also showed comparable genomic aberrations with the corresponding primary tumor and exhibit gene set enrichment of multiple ovarian cancer molecular subtypes, similar to patient tumors. Importantly, each of these tumorgraft models is annotated with clinical data and for those that have been tested, response to platinum chemotherapy correlates with the source patient. Conclusions: Presented herein is the largest known living tumor bank of patient-derived, ovarian tumorgraft models that can be applied to the development of personalized cancer treatment. Clin Cancer Res; 20(5); 1288–97. ©2014 AACR.
Pediatric Endocrine Surgery: A 20-Year Experience at the Mayo Clinic
Kundel, Anna, Thompson, Geoffrey B. , Richards, Melanie L., Qiu, Lizhen, Cai, Yefeng , Schwenk, Frederick W., Lteif, Aida, Pittock, Siobhán T. , Kumar, Seema , Tebben, Peter J. , Grant, Clive S., Hay, Ian , Tebben, Peter

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 12, 2013 | Volume: 99 | Issue: 2 | Pages: 399-406

10.1210/jc.2013-2617 | PMID 24423286 Get It

Neuroimaging and clinical features in type II (late-onset) Alexander disease
Graff‐Radford, Jonathan , Schwartz, Kara M., Gavrilova, Ralitza H. , Kumar, Neeraj , Lachance, Daniel Honore

Mayo Clinic

Neurology | December 5, 2013 | Volume: 82 | Issue: 1 | Pages: 49-56

10.1212/01.wnl.0000438230.33223.bc | PMID 24306001 Get It